Lumateperone for Major Depressive Disorder
Trial Summary
What is the purpose of this trial?
This trial is testing lumateperone, a medication that may help people with depression who haven't improved with other treatments. The study includes patients diagnosed with Major Depressive Disorder who haven't responded well to their current antidepressants. Lumateperone works by balancing brain chemicals that affect mood, potentially improving depressive symptoms.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop your current medications, but it requires that you have an inadequate response to at least two antidepressants and continue taking one of them at the minimum effective dose for at least six weeks.
Is Lumateperone safe for humans?
How is the drug lumateperone different from other treatments for major depressive disorder?
Lumateperone is unique because it is a first-in-class drug that simultaneously affects serotonin, dopamine, and glutamate systems in the brain, which is different from most other treatments that typically target only one or two of these pathways. It is also taken orally and has been shown to improve a wide range of depression symptoms in people with bipolar disorder, suggesting potential benefits for major depressive disorder.35678
Eligibility Criteria
This trial is for adults aged 18-65 with Major Depressive Disorder (MDD) who haven't had enough improvement from their current antidepressant treatment. They must have been on a stable dose of certain antidepressants for at least 6 weeks and meet specific criteria indicating moderate to severe depression.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either placebo or lumateperone 42 mg/day in a double-blind manner
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Lumateperone (Other)
- Placebo (Placebo)